Personalised mRNA vaccine reduces melanoma recurrence risk by 42%

An Australian-led phase 3 trial found that adding the custom-made vaccine intismeran to immunotherapy significantly improved outcomes for melanoma patients.

A personalised mRNA cancer vaccine has reduced the risk of melanoma recurrence or death by 42 per cent compared to immunotherapy alone. The Australian-led phase 3 trial involved 1,137 patients whose melanoma had been surgically removed but were at high risk of it returning. All participants had not previously received any cancer drug treatment.

The treatment combines the personalised vaccine, intismeran, with the immunotherapy drug pembrolizumab. Intismeran is custom-made to target up to 34 genetic mutations unique to an individual's melanoma. This mRNA-based vaccine uses genetic information from a patient's tumour to establish a target for the immune system.

At two years post-treatment, 82 per cent of those receiving the combination were alive and recurrence-free, compared with 70 per cent of participants treated with pembrolizumab alone. Professor Georgina Long, medical director of the Melanoma Institute Australia, said the results were better than she had hoped and represent a foundational shift in how scientists harness the immune system.

Professor Long will present the findings at the European Society for Medical Oncology's annual congress in Madrid this weekend.

The results have been accepted for publication in the New England Journal of Medicine. The personalised vaccine will not be available as a standard melanoma treatment until it has gone through further study and regulatory review, a process that may take several years.

Drug manufacturers said it was too early to tell from the data whether the combination treatment improved long-term survival.

Key facts

  • The combination of intismeran and pembrolizumab reduced the risk of melanoma recurrence or death by 42 per cent.
  • The phase 3 trial included 1,137 patients across 157 sites globally.
  • Intismeran is a personalised mRNA vaccine targeting up to 34 unique gene mutations.

Three perspectives

Neutral

The trial found that the combination of intismeran and pembrolizumab reduced melanoma recurrence or death risk by 42 per cent compared to pembrolizumab alone.

Positive

Professor Georgina Long described the results as a foundational shift in the way scientists harness the immune system to target cancer.

Negative

A significant portion of patients do not respond to the vaccine in the first instance, and it is too early to determine if the treatment improves long-term survival.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyNHS staff inappropriately accessed patient records over 3,000 times

All sections

Edition